What is a glucagonomist?

Glucagonomist is a rare type of tumor that is formed in the pancreas. Generally malignant in the composition, the glucagonomist has increased potential to metastasize to other organs, namely the liver. Treatment of this serious health usually involves administration of chemotherapy and in some cases surgery. Islets are responsible for the production and release of pancreatic hormones such as glucagon and insulin. There is no known cause of the development of abnormal island cells that leads to the formation of glucagonomics. In the presence of this type of tumor, glucagon production increases to the extent that it is produced into the body and releases too much hormone.

individuals with this type of pancreatic tumor can show and experience different symptoms and symptoms. Some may develop sporadic skin rashes that occur as lesions or dry, scaly patch that affects the face, torso or lower limbs. Inflammation of the oral cavity, frequent urination and excessive thirst may also be symptoms of present presentThe tumor of this type of pancreatic tumor. Individuals can also develop intolerance of glucose or high blood sugar, also known as hyperglycemia. Other symptoms may include unintentional weight loss and diarrhea.

There are several diagnostic tests that can be performed to confirm the presence of glucagonomics; Although it is important to realize that in most cases at a time when the glucagonomist is detected, she has already metastasized to the liver. Individuals can undergo computer tomography (CT) abdominal scanning to evaluate the condition of the pancreas and surrounding organs in the digestive system. Blood tests can be performed to measure glucagon and glucose levels and to control abnormalities or markers indicating the presence of malignancy. In addition, glucose tolerance can be performed to assess how the individual's body metabolizes blood sugar.

Treatment of GlukagOnoma usually includes the use of chemotherapy to reduce the tumor. Chemotherapy is a form of anti -cancer medicinal therapy that can be administered orally or intravenously. Individuals undergoing chemological treatment may have side effects that may include fatigue, nausea and vomiting. If the glucagonomist does not respond to chemotherapy, surgery may be performed to remove the tumor. In general, surgical removal of abnormal growth is preferred to prevent the spread of cancer and the development of complications.

The

prognosis associated with the glucagonomist depends on the size and composition of the tumor and whether it has metastasized or not. The chances of growth metastasis are relatively high and may disrupt the success of treatment. When Tum or remains limited to the pancreas of the pancreas and is successfully removed, the five -year survival rate increases significantly.